Vorapaxar in the Secondary Prevention of Atherothrombotic Events
David A. Morrow(University of California, San Francisco), Sabina A. Murphy(Brigham and Women's Hospital), Keith A.A. Fox(University of Edinburgh), Jindřich Špinar(Masaryk University), Benjamin M. Scirica(Brigham and Women's Hospital), Ernesto Paolasso, John Strony(University Hospitals of Cleveland), Marc P. Bonaca(The Medical Center of Aurora), Xuan Liu(Fudan University), Stephen D. Wiviott(Brigham and Women's Hospital), A.J. Oude Ophuis(Noordwest Ziekenhuisgroep), Sebastián F. Ameriso(Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia), Leslie Lipka(United States Nuclear Regulatory Commission), Pierre Théroux(Montreal Heart Institute), Mary Polly Fish(Brigham and Women's Hospital), José Carlos Nicolau(Hospital São Paulo), Anthony J. Dalby(Milpark Hospital), Eugene Braunwald(Mass General Brigham)
Cited by 941
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k